Data from the UK’s Medicines and Healthcare products Regulatory Agency reveals substantial improvements in regulatory efficiency, with average medicine assessment times dropping from 210 days in 2025 to 143 days in 2026. This 32% reduction in processing duration resulted from enhanced digital assessment tools and streamlined evaluation protocols implemented across the agency’s clinical updates division. The acceleration particularly benefited oncology applications, where 11 new cancer therapies received rapid approval through the Priority Medicines (PRIME) scheme—an initiative aligned with the European Medicines Agency. The MHRA’s accelerated pathways achieved an average reduction of 67 days in total approval timelines. This efficiency gain demonstrates how regulatory modernisation can expedite patient access to life-changing therapeutics without compromising safety standards or scientific rigour.
Was this article helpful?
